Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 19767035)

1.

[Coexistence of antitopoisomerase I and anticentromere antibodies in systemic sclerosis].

Garrido Rasco R, Castillo Palma MJ, García Hernández FJ, Sánchez Román J.

Med Clin (Barc). 2010 Sep 18;135(9):430-1. doi: 10.1016/j.medcli.2009.07.006. Epub 2009 Sep 20. Spanish. No abstract available.

PMID:
19767035
2.

Is the measurement of anti-PM-1α antibodies at least as important as that of other systemic sclerosis-specific antibodies? Comment on the article by D'Aoust et al.

Muro Y, Sugiura K, Akiyama M.

Arthritis Rheumatol. 2014 Nov;66(11):3248. doi: 10.1002/art.38803. No abstract available.

PMID:
25077816
3.

Reply: To PMID 24577935.

D'Aoust J, Hudson M, Baron M, Mahler M, Fritzler MJ.

Arthritis Rheumatol. 2014 Nov;66(11):3249-50. doi: 10.1002/art.38801. No abstract available.

PMID:
25077459
4.

Proteome-wide analysis and CXCL4 in systemic sclerosis.

Mathian A, Miyara M, Gorochov G.

N Engl J Med. 2014 Apr 17;370(16):1562. doi: 10.1056/NEJMc1402401#SA3. No abstract available.

PMID:
24738679
5.

Proteome-wide analysis and CXCL4 in systemic sclerosis.

Su R, Schmajuk G.

N Engl J Med. 2014 Apr 17;370(16):1562. doi: 10.1056/NEJMc1402401#SA2. No abstract available.

PMID:
24738678
6.

Proteome-wide analysis and CXCL4 in systemic sclerosis.

George PM, Wort SJ, Mitchell JA.

N Engl J Med. 2014 Apr 17;370(16):1561-2. doi: 10.1056/NEJMc1402401#SA1. No abstract available.

PMID:
24738677
7.

Proteome-wide analysis and CXCL4 in systemic sclerosis.

van Roon JA, Tesselaar K, Radstake TR.

N Engl J Med. 2014 Apr 17;370(16):1563-4. doi: 10.1056/NEJMc1402401. No abstract available.

8.

[Systemic sclerosis autoantibodies: what dermatologists must know].

Hüe S, Ingen-Housz-Oro S, Cosnes A.

Ann Dermatol Venereol. 2013 Feb;140(2):143-9. doi: 10.1016/j.annder.2012.11.012. Epub 2013 Jan 16. Review. French. No abstract available.

PMID:
23395500
9.

Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study.

Heijnen IA, Foocharoen C, Bannert B, Carreira PE, Caporali R, Smith V, Kumánovics G, Becker MO, Vanthuyne M, Simsek I, Bocelli-Tyndall C, Walker UA.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):96-102. Epub 2012 Oct 24.

PMID:
23101460
10.

Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with antitopoisomerase I antibody and more severe disease in systemic sclerosis.

Bielecki M, Kowal K, Lapinska A, Bernatowicz P, Chyczewski L, Kowal-Bielecka O.

J Rheumatol. 2010 Nov;37(11):2286-9. doi: 10.3899/jrheum.100454. Epub 2010 Sep 1.

PMID:
20810514
11.

Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis.

Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM.

Arthritis Res Ther. 2010;12(2):R47. doi: 10.1186/ar2958. Epub 2010 Mar 13.

12.

Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.

Faucher B, Stein P, Granel B, Weiller PJ, Disdier P, Serratrice J, Harlé JR, Durand JM, Frances Y, Guis S, Pham T, Bardin N, Sanmarco M.

Eur J Intern Med. 2010 Apr;21(2):114-7. doi: 10.1016/j.ejim.2010.01.004. Epub 2010 Feb 8.

PMID:
20206882
13.

Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.

Hamaguchi Y.

J Dermatol. 2010 Jan;37(1):42-53. doi: 10.1111/j.1346-8138.2009.00762.x. Review.

PMID:
20175839
14.

Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors.

Ingraham KM, O'Brien MS, Shenin M, Derk CT, Steen VD.

J Rheumatol. 2010 Mar;37(3):603-7. doi: 10.3899/jrheum.090600. Epub 2010 Jan 15.

PMID:
20080908
15.

IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Martínez-Cordero E, Trejo AP, León DE.

J Clin Lab Anal. 2009;23(6):408-16. doi: 10.1002/jcla.20342.

PMID:
19927342
16.

Antibody response to pneumococcal polysaccharide vaccine in systemic sclerosis.

Mercado U, Acosta H, Diaz-Molina R.

J Rheumatol. 2009 Jul;36(7):1549-50. doi: 10.3899/jrheum.081227. No abstract available.

PMID:
19567636
17.

Anti-topoisomerase I autoantibodies in systemic sclerosis.

Czömpöly T, Simon D, Czirják L, Németh P.

Autoimmun Rev. 2009 Jul;8(8):692-6. doi: 10.1016/j.autrev.2009.02.018. Epub 2009 Feb 13. Review.

PMID:
19393194
18.

Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.

Simon D, Czömpöly T, Berki T, Minier T, Peti A, Tóth E, Czirják L, Németh P.

Int Immunol. 2009 Apr;21(4):415-22. doi: 10.1093/intimm/dxp008. Epub 2009 Feb 11.

19.

Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis.

Majone F, Olivieri S, Cozzi F, Montaldi A, Tonello M, Visentin MS, Ciprian L, Ruffatti A.

Rheumatol Int. 2009 Jun;29(8):891-5. doi: 10.1007/s00296-008-0799-x. Epub 2008 Dec 3.

PMID:
19050892
20.

Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody.

Komura K, Yanaba K, Ogawa F, Shimizu K, Takehara K, Sato S.

Clin Exp Dermatol. 2008 May;33(3):329-32. doi: 10.1111/j.1365-2230.2007.02678.x. Epub 2008 Feb 28.

PMID:
18312458
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk